Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system by Di Menna, Luisa et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.neuropharm.2017.10.026
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Di Menna, L., Joffe, M. E., Iacovelli, L., Orlando, R., Lindsley, C. W., Mairesse, J., ... Nicoletti, F. (2018).
Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous
system. Neuropharmacology, 128, 301-313. https://doi.org/10.1016/j.neuropharm.2017.10.026
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors
in the central nervous system
Luisa Di Menna, Max E. Joffe, Luisa Iacovelli, Rosamaria Orlando, Craig W. Lindsley,
Jèrome Mairesse, Pierre Gressèns, Milena Cannella, Filippo Caraci, Agata Copani,
Valeria Bruno, Giuseppe Battaglia, P. Jeffrey Conn, Ferdinando Nicoletti
PII: S0028-3908(17)30493-8
DOI: 10.1016/j.neuropharm.2017.10.026
Reference: NP 6911
To appear in: Neuropharmacology
Received Date: 25 May 2017
Revised Date: 9 October 2017
Accepted Date: 21 October 2017
Please cite this article as: Di Menna, L., Joffe, M.E., Iacovelli, L., Orlando, R., Lindsley, C.W., Mairesse,
Jè., Gressèns, P., Cannella, M., Caraci, F., Copani, A., Bruno, V., Battaglia, G., Conn, P.J., Nicoletti,
F., Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central
nervous system, Neuropharmacology (2017), doi: 10.1016/j.neuropharm.2017.10.026.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Functional partnership between mGlu3 and mGlu5 metabotropic glutamate 
receptors in the central nervous system 
 
 
Luisa Di Menna1*, Max E. Joffe2*, Luisa Iacovelli3*, Rosamaria Orlando3, Craig W. Lindsley2, 
Jèrome Mairesse4, Pierre Gressèns4,5, Milena Cannella1, Filippo Caraci6,7, Agata Copani6,8, Valeria 
Bruno1,3, Giuseppe Battaglia1, P. Jeffrey Conn2#, Ferdinando Nicoletti1,3# 
 
1I.R.C.C.S. Neuromed, 86077 Pozzilli, Italy; 2Vanderbilt Center for Neuroscience Drug Discovery, 
Vanderbilt University Medical Center, Nashville, TN 37232-0697, USA; 3Department of 
Physiology and Pharmacology, University Sapienza of Roma, 00185 Roma, Italy; 4PROTECT, 
INSERM, Université Paris Diderot, Sorbonne Paris Cité, 1141 Paris, France; 5Centre for the 
Developing Brain, Department of Perinatal Health and Imaging, Division of Imaging Sciences and 
Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, 
London SE1 7EH, United Kingdom; 6Department of Drug Sciences, University of Catania, 95125 
Catania, Italy; 7I.R.C.C.S. Oasi Maria SS, 94018 Troina, Italy; 8Institute of Biostructure and 
Bioimaging, National Research Council, 95126 Catania, Italy. 
 
*Co-first Authors     #Co-last Authors 
 
 
Key words: Metabotropic glutamate receptors; polyphosphoinositide hydrolysis; synaptic 
plasticity; receptor-receptor cross-talk; neurodevelopment; long-term depression; neuronal death; 
G-protein βγ subunits.   
 
Address all correspondence to:  
Ferdinando Nicoletti, MD,  
Department of Physiology and Pharmacology,  
University Sapienza of Roma,  
Piazzale Aldo Moro, 5,  
00185 Roma,  
Italy 
Tel:. +39-06-49912969 
Fax: +39-0865-927575 
E-mail: ferdinandonicoletti@hotmail.com  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
Abstract 
 
mGlu5 receptors are involved in mechanisms of activity-dependent synaptic plasticity, and are 
targeted by drugs developed for the treatment of CNS disorders. We report that mGlu3 receptors, 
which are traditionally linked to the control of neurotransmitter release, support mGlu5 receptor 
signaling in neurons and largely contribute to the robust mGlu5 receptor-mediated 
polyphosphoinositide hydrolysis in the early postnatal life. In cortical pyramidal neurons, mGlu3 
receptor activation potentiated mGlu5 receptor-mediated somatic Ca2+ mobilization, and mGlu3 
receptor-mediated long-term depression in the prefrontal cortex required the endogenous activation 
of mGlu5 receptors. The interaction between mGlu3 and mGlu5 receptors was also relevant to 
mechanisms of neuronal toxicity, with mGlu3 receptors shaping the influence of mGlu5 receptors 
on excitotoxic neuronal death. These findings shed new light into the complex role played by mGlu 
receptors in physiology and pathology, and suggest reconsideration of some of the current dogmas 
in the mGlu receptor field. 
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1. Introduction 
 
mGlu5 receptors mediate processes of activity-dependent synaptic plasticity underlying learning 
and memory, and are candidate drug targets for disorders of the central nervous system (CNS) 
(Vinson and Conn, 2012; Nicoletti et al., 2015). Abnormalities in the expression or function of 
mGlu5 receptors are associated with schizophrenia (Ohnuma et al., 1998; Matosin et al., 2016), 
focal cortical dysplasia (Dubois et al. 2016), absence epilepsy (D’Amore et al., 2015), Down’s 
syndrome (Iyer et al., 2014), neuropathic pain (Lin et al., 2015), Fragile-X syndrome, and other 
types of monogenic autism (Huber et al., 2002; Giuffrida et al., 2005; Ronesi et al., 2012; D’Antoni 
et al., 2014; Pignatelli et al., 2014). Canonical mGlu5 receptor signaling proceeds through the 
hydrolysis of polyphosphoinositides (PI). PI hydrolysis precipitates the formation of inositol-1,4,5-
trisphosphate (InsP3) and diacylglycerol, which stimulate intracellular Ca2+ release and protein 
kinase C (PKC), respectively (Nicoletti et al., 2011). mGlu5 receptor-mediated PI hydrolysis is 
dramatically high during early postnatal life and progressively declines across CNS maturation 
(Nicoletti et al., 1986a; Casabona et al., 1997). Not surprisingly, mGlu5 receptor signaling has been 
shown to regulate cortical development and has been implicated in neuronal migration, dendritic 
outgrowth, and synaptic formation and elimination (Reid et al., 1997; Hannan et al., 2001; 
Wijetunge et al., 2008; Ballester-Rosado et al., 2016). Mice lacking mGlu5 receptors show 
developmental abnormalities in the prefrontal cortex (PFC) and hippocampus that are typically 
associated with schizophrenia, such as reduced expression of reelin, glutamate decarboxylase-65 
and -67, and parvalbumin mRNA levels (Luoni et al., 2016). Intracellular mechanisms underpinning 
mGlu5 receptor signaling have been extensively characterized. Scaffolding proteins, such as Homer 
and Shank, link mGlu5 receptors to a variety of effector proteins (Brakeman et al., 1997; Xiao et al., 
1998; Tu et al., 1999; Ango et al., 2000; Rong et al., 2003; Kammermeier et al., 2007), and 
disruptions in mGlu5 receptor-Homer interactions underlie abnormalities associated with several 
disease states (Giuffrida et al., 2005; Ronesi et al., 2012; D’Antoni et al., 2014; Guo et al., 2016). In 
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contrast, less is known about how other membrane receptors regulate mGlu5 receptor signaling. 
Activation of NMDA receptors has been shown to potentiate mGlu5 receptor function by 
restraining mGlu5 receptor desensitization via activation of protein phosphatase 2B/calcineurin 
(Alagarsamy et al., 1999; 2002; 2005). In addition, a reciprocal interaction between A2A adenosine 
receptors and mGlu5 receptors has been consistently observed in striatal projection neurons (Diaz-
Cabiale et al., 2002; Ferre et al., 2002; Nishi et al., 2003; Coccurello et al., 2004; Domenici et al. 
2004). Despite these reports, very little is known about how mGlu5 receptor function is regulated 
by other subtypes of mGlu receptors. 
We now report that activation of mGlu3 receptors amplifies mGlu5 receptor signaling and that the 
functional partnership between mGlu3 and mGlu5 receptors mediates the robust stimulation of PI 
hydrolysis induced by excitatory amino acids in the developing brain. In addition, we demonstrate 
that mGlu3 activation potentiates mGlu5 receptor-mediated somatic Ca2+ mobilization in cortical 
pyramidal neurons and mGlu5 receptor activity is required for mGlu3 receptor-dependent long-term 
depression (LTD) in the PFC. Finally, we demonstrate that neuronal mGlu3 receptors shape mGlu5 
receptor function in mechanisms of neurodegeneration, with mGlu5 receptors switching from 
neurotoxic to neuroprotective when mGlu3 receptors are selectively inhibited. Together, these data 
provide compelling evidence for a novel functional interaction between mGlu3 and mGlu5 
receptors. This functional interaction underlies the dramatic developmental changes in mGlu 
receptor signaling as well as neuronal mGlu receptor function and synaptic plasticity in the adult 
PFC. 
 
 
2. Materials and Methods 
 
(RS)-3,5-dihydroxyphenylglycine (DHPG), (-)-2-oxa-4-aminocyclo[3.1.0]hexane-4,6-dicarboxylic 
acid (LY379268) and 6-cyano-7-nitroquinoxaline-2,3-dione were purchased from Tocris Bioscience 
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(Bristol, UK). 3,4-Dihydro-2H-pyrano[2,3-b]quinolin-7-yl-(cis-4-methoxycyclohexyl)-methanone 
(JNJ16259685), 2-methyl-6-(phenylethynyl) pyridine (MPEP) and N-methyl-D-aspartate (NMDA) 
were purchased from Tocris Bioscience. 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine 
hydrochloride (MTEP), VU0469650, VU0650786 and VU6001966 were synthesized in house. 
Tetrodotoxin was purchased from Sigma. Myo-[3H]inositol (18 Ci/mmol) was purchased from 
PerkinElmer (Milan, Italy). JNJ16259685, VU0650786, VU0469650 and VU6001966 were 
dissolved in dimethyl sulfoxide (DMSO) at the initial concentration of 10 mM. The final 
concentration of DMSO applied to the cultures was 0.1%. NMDA, MPEP and MTEP were 
dissolved in distilled H2O at the initial concentration of 10 mM. DHPG was dissolved in Krebs 
buffer at the initial concentration of 10 mM. LY379268 was dissolved in distilled H2O + 1.1 mEq 
NaOH at the initial concentration of 10 mM and diluted in Krebs at the final concentration. 
 
2.1 HEK 293 cells for assessment of mGlu receptor-stimulated PI hydrolysis 
Human embryonic kidney (HEK) 293 cells (ATCC, Cat# CRL-1573) were cultured in DMEM 
containing 10% fetal calf serum, and transfected as described previously (Iacovelli et al., 2014). The 
plasmid encoding for the C-terminal domain of GRK2 (Gly495-Leu689) (GRK2-Cter) was kindly 
provided by C. Scorer (GlaxoSmithKline, Uxbridge, Middlesex, UK); mGlu2 receptor cDNA was 
kindly provided by J. Blahos (Academy of Science, Prague, Czech Republic). mGlu3 receptor 
cDNA was kindly provided by F. Ferraguti (Innsbruck Medical University, Innsbruck, Austria); 
human mGlu1
 
receptor cDNA and mGlu5 receptor cDNA were kindly provided by M. Corsi (Glaxo 
Wellcome, Verona, Italy).  
 
2.2 Preparation of pure primary neuronal cell cultures 
Experiments were performed according to the Institutional Animal Care and Use Committee of the 
University of Catania. Cultures of pure cortical neurons were prepared from male and female rats at 
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embryonic day 15. Briefly, cortices were dissected in Ca2+/Mg2+-free buffer and mechanically 
dissociated. Cortical cells were plated at a density of 0.45 x 106/well on 48 well multiplates (Costar, 
Corning Inc., NY) pre-coated with 0.1 mg/ml poly-D-lysine (Sigma-Aldrich, Milan, Italy) in 
NeuralQ Basal Medium (GSM-9420, MTI-Global Stem, Gaithersburg, MD), a serum-free basal 
medium optimized for maximum growth and survival of primary neurons in culture, supplemented 
with GS21Tm Neural Supplement (GSM-3100, MTI-Global Stem) and 2 mM glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. Cytosine-D-arabinofuranoside (10 µM) was added to the 
cultures 18 hr after plating to avoid the proliferation of non-neuronal elements and maintained for 3 
days before partial replacement of the medium. This method yielded nearly pure neuronal cultures 
with <2% of glial cells (Copani et al., 1999).  
 
2.3 Preparation of primary reactive astrocytes 
Primary cultures of mouse cortical astrocytes were prepared as described previously (Caraci et al., 
2011). Briefly, astrocyte cell cultures were prepared from male and female CD1 mice at 1-3 days 
after birth. Dissociated cortical cells were grown in 15-mm multiwell vessels (Falcon Primaria, 
Lincoln Park, NJ) using a plating medium of MEM-Eagle’s salts supplemented with fetal bovine 
serum (10%), horse serum (10%), glutamine (2 mM), glucose (21 mM) and 100 U/ml penicillin, 
and 100 µg/ml streptomycin. For the induction of a reactive phenotype, we followed the protocol 
described in (Miller et al., 1995). In brief, cultured astrocytes at 6 DIV were shaken overnight to 
remove microglia and oligodendrocytes, and then switched into serum-free medium containing 
growth factors (Caraci et al., 2011). 
 
2.4 Immunoblotting of mGlu receptors in transfected HEK 293 cells 
Co-transfected HEK 293 cells were rinsed in ice-cold PBS and solubilized in Triton X-lysis buffer 
(10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM sodium 
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orthovanadate, 50 mM sodium fluoride, and 10 mM β-glycerophosphate). Protein cell lysates (80 
µg) were separated by SDS-PAGE electrophoresis, blotted onto nitrocellulose, and probed using a 
mouse anti-mGlu1 receptor antibody (1:1000; BD Bioscience, Milano, Italy; cat# 556389) or a 
rabbit anti-mGlu5 receptor antibody (1:1000; Millipore; Billerica, MA; cat# AB5675). The 
immunoreactive bands were visualized by enhanced chemiluminescence (GE Health care, 
Buckinghamshire, UK) using horseradish peroxidase-conjugated secondary antibodies. 
 
2.5 Assessment of mGlu receptor-stimulated PI hydrolysis in HEK 293 cells 
Forty-eight hr after transfection, HEK 293 cells were seeded in 12-well plates and exposed to 2 
µCi/ml of myo-[3H]inositol for 24 hr. Afterwards, cells were washed in Krebs-Hensleit buffer 
equilibrated with 95% O2, 5% CO2 to pH 7.4, containing 10 mM LiCl, and DHPG (300 µM) and/or 
LY379268 (5 µM) were added and maintained in the incubation buffer for additional 30 min. The 
reaction was stopped with ice cold methanol. After scraping, the cells were collected and methanol, 
water, and chloroform were added (1 :1 :1, final). The [3H]inositolmonophosphate (InsP) present in 
the aqueous phase was separated by anion exchange chromatography in 10-ml columns containing 
1.5 ml of Dowex 1-X-8 resin (formate form, 100-200 mesh, Bio-Rad, Milan, Italy). Columns were 
washed twice with water, once with a solution of 5 mM sodium tetraborate and 40 mM sodium 
formate, and the [3H]InsP was eluted with 6.5 ml of 0.2 M ammonium formate and 0.1 M of formic 
acid.  
 
2.6 Assessment of NMDA toxicity in pure cultures of rat cortical neurons 
Mature cell cultures (13 DIV) were exposed for 20 min to low (75 µM) or high (300 µM) 
concentrations of NMDA and/or DHPG (100 µM) and VU0650786 (10 µM) in a 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered salt solution containing 0.8 mM 
Mg2+, 10 µM L-glycine, and JNJ16259685 (10 µM) to prevent the activation of mGlu1 receptors. 
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After the 20-min pulse, cell cultures were maintained for 22-24 hr in NeuralQ Basal Medium and 2 
mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, without GS21Tm. Neuronal injury 
was measured by either trypan blue staining (0.4% for 10 min) or the MTT assay (Caraci et al., 
2016). 
 
2.7 RNA isolation, reverse transcription and quantitative real-time PCR 
Total RNA was extracted from primary reactive astrocytes with Trizol reagent according to 
manufacturer's protocol. The RNA was further treated with DNase (Qiagen, Hilden, Germany) and 
single strand cDNA was synthesized from 2 µg of total RNA using superscript III (Invitrogen, 
Carlsbad, CA) and random hexamers. Real-time PCR was performed on 20 ng of cDNA by using 
specific primers and Ssoadvanced Universal SYBR Green on an Applied Biosystems Step-One 
instrument. Thermal cycler conditions were as follows: 10 min at 95°C, 40 cycles of denaturation 
(15 sec at 95°C), and combined annealing/extension (1 min at 60°C). Primers used were as follows: 
Grm1 Forw AAATCTACAGCAATGCTGGCGA and Rev CTTCGATGACTTCATCTCTGTC; 
Grm2 Forw ACCAGAAGGGTGGCCCAGCA and Rev GCACCCCAGGCAGCAGATGG; Grm3 
Forw CAGCAAGCTCCCTCTTTTGT and Rev GCTAAAAGAGCCCGTCACTG; Grm5 Forw 
ACGAAGACCAACCGTATTGC and Rev AGACTTCTCGGATGCTTGGA; and GAPDH Forw 
CGTCCCGTAGACAAAATGGT and Rev TCAATGAAGGGGTCGTTGAT. 
mRNA copy number of each gene analyzed was calculated from serially diluted standard curves 
simultaneously amplified with the samples and normalized against GAPDH copy number.  
 
2.8 Assessment of PI hydrolysis in primary reactive astrocytes 
Reactive astrocyte cultures seeded in 24-multiwells were labeled with 1 µCi/well of myo-
[3H]inositol overnight, and then challenged with DHPG (20 or 100 µM) and/or LY379268 (1 µM) 
and VU0650786 (10 µM)  in the presence of 10 mM LiCl for 1 hr. PI hydrolysis was measured as 
described above. 
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2.9 Animals used for preparation of brain slices for PI hydrolysis measurements 
Studies were performed in accordance with the national and international guidelines and regulations 
on animal care and use and were approved by the Neuromed Institutional Animal Care and Use 
Committee. All efforts were made to minimize animal suffering and to reduce the number of 
animals used. Animals were housed under controlled conditions (temperature, 22°C; humidity, 
40%) with a 12 hr light/dark cycle and food and water ad libitum. CD1 male and female mice at 
different ages (from postnatal day (PND)8/9 to PND13/14) and CD1 male mice at 30 and 60 PND 
(Charles River Laboratories, Calco, Italy). mGlu5 receptor knockout (mGlu5-/-) male mice and their 
male wild-type counterparts at PND15. mGlu5 heterozygous mice were originally purchased from 
the Jackson Laboratories (Bar Harbor, ME, B6.129-Grm5tm1Rod/J, stock # 003558). Mice 
heterozygous for the targeted mutation were backcrossed to homozygosity and all mice used were 
generated by heterozygous breeding. Crv4 male mice lacking mGlu1 receptors at PND 15 and their 
male wild-type counterparts. Crv4 mice are mice of a BALB/c/Pas inbred strain carrying a 
spontaneous recessive mutation that consists of a LTR insertion that disrupts the splicing of the 
Gm1 gene encoding for mGlu1 receptors (Conti et al., 2006). These mice were kindly provided by 
A. Puliti (University of Genoa, Italy). mGlu2 receptor knockout (mGlu2-/-) and mGlu3 receptor 
knockout (mGlu2-/-) male and female mice at PND9/10 and PND13/14. mGlu2-/- mice, mGlu3-/- 
mice, and their CD1 wild-type counterparts were kindly provided by Eli Lilly & Company 
(Indianapolis, IN) (Linden et al., 2005). 
 
2.10 Animals used for preparation of brain slices for Ca2+ imaging and LTD experiments 
Adult (8-12 week) male C57Bl6/J mice were used. Mice were housed in groups (2-5 per cage) on a 
standard 12-hr light cycle (lights on at 6:00 am) with food and water ad libitum. All experimental 
protocols were approved by the Vanderbilt Institutional Animal Care and Use Committee. 
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2.11 Measurement of PI hydrolysis in brain slices 
Measurements of PI hydrolysis in cortical slices were performed as described in detail (Nicoletti et 
al., 1986b). Cortical slices were prepared from CD1 male and female mice at different ages (from 
PND8/9 to PND13/14); from CD1 male mice at PND30 and PND60; from mGlu5-/- male mice and 
their male wild-type counterparts at PND15; from crv4 male mice at PND 15 and their male wild-
type counterparts; and from mGlu2-/- and mGlu3-/- male and female mice at PND9/10 and 
PND13/14. Animals were killed by decapitation, and brain regions were dissected out and 
transferred in ice-cold Krebs-Henseleit buffer (NaCl 118 mM, KCl 4.7 mM, MgSO4 1.18 mM, 
KH2PO4 1.18 mM, NaHCO3 24.8 mM, CaCl2 1.2 mM, D-glucose 10 mM) that had been pre-gassed 
with 95% O2 and 5% CO2 to pH 7.4. Slices (350×350 µm) were prepared by a Mc Ilwain tissue 
chopper. Forty µl of gravity packed slices were then incubated for 60 min in 350 µl buffer 
containing 1 µCi of myo-[3H]inositol. Slices were incubated with LiCl (10 mM, for 10 min) 
followed by mGlu receptor ligands. One hr later, the incubation was stopped by the addition of 900 
µl methanol:chloroform (2:1). After further addition of 300 µl chloroform and 600 µl water, 
samples were centrifuged at low speed to facilitate phase separation and the [3H]InsP present in the 
supernatant was separated by anion exchange chromatography as detailed above. For protein 
measurements samples were dryed after removal of the water phase and incubated with 0.5 N 
NaOH at 50°C for 2 hr. Proteins were measured as described by Lowry et al., 1951. 
 
2.12 Ca2+ imaging and LTD in the mouse PFC 
For Ca2+ imaging and LTD, all drugs were prepared at 1000X, aliquoted, frozen, and thawed on the 
day of use. LY379268, DHPG, and MTEP were prepared in purified water. VU0650786 and 
VU0469650 were prepared in DMSO. LY279268, DHPG, and tetrodotoxin were purchased from 
Abcam. MTEP, VU0650786, and VU0469650 were synthesized in-house. 
Mice were deeply anesthetized with isoflurane and decapitated for acute brain slice preparation. The 
brain was quickly removed and placed in ice-cold cutting/recovery solution (in mM): 93 N-methyl-
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D-glucamine, 20 HEPES, 2.5 KCl, 0.5 CaCl2, 10 MgCl2, 1.2 NaH2PO4, 25 glucose, 5 Na-ascorbate, 
and 3 Na-pyruvate. Coronal slices (300 µM) containing the PFC were prepared using a Leica 
VT1000S vibratome and immediately transferred to a heated (34 ± 1°C) bath containing the 
recovery solution for 10 min. Slices were then transferred to a room-temperature (23 ± 1°C) holding 
chamber filled with artificial cerebrospinal fluid (aCSF) (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 
1.3 MgCl2, 1 NaH2PO4, 11 glucose, and 26 NaHCO3. After at least 60 min, slices were placed in the 
recording chamber and perfused with fresh, warm (30 ± 1°C) aCSF at 2 ml/min. All solutions were 
continuously oxygenated (95% O2/5% CO2). 
Pyramidal cells in layer 5 of the PFC were visually identified by differential interference contrast on 
an upright microscopy (Olympus, BX51WI). Borosilicate glass electrodes (2-4 MΩ) were pulled 
using a Flaming/Brown micropipette puller (Sutter, P-1000) and filled with a potassium-based 
internal solution (in mM): 125 K-gluconate, 4 NaCl, 10 HEPES, 4 MgATP, 0.3 NaGTP, 10 Tris-
phosphocreatine. Before all experiments, cells were verified as regular-spiking by their 
characteristic spike-firing adaptation in response to increasing current injections. Fast-spiking 
neurons (putative interneurons) were discarded. Local glutamate release was elicited at 0.1 Hz by 
0.1-0.15 ms electrical stimulation from a concentric bipolar electrode (CBARC75, FHC Inc) placed 
slightly medial to the recording electrode in layer 5. To preclude recording inhibitory post-synaptic 
currents, all long-term recordings were performed in voltage-clamp configuration at -70 mV. 
Excitatory post-synaptic currents (EPSCs) were completely blocked by 6-cyano-7-nitroquinoxaline-
2,3-dione (data not shown). After acquiring a stable baseline recording, 100 nM LY379268 and/or 
100 µM DHPG was applied to the slice for 3 or 10 min to elicit LTD. NAM application occurred 
for at least 5 mins prior to and co-terminated with LY379268/DHPG. Recordings were acquired 
with a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA), filtered at 2 kHz and 
digitized at 10 kHz. Data acquisition and analysis were performed using pClamp 10.4 software 
(Axon Instruments, Union City, CA).  
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Ca2+ imaging experiments were performed as described (Foster et al., 2014). The membrane-
impermeable fluorescent Ca2+ indicator Fluo-4 (0.1 mM pentapotassium salt) was added to the 
internal solution and cells were dialyzed for at least 15 min prior to imaging. The relative difference 
in fluorescence between the soma and background was quantified and monitored at 1 Hz with 5-50 
ms light stimulation from a mercury light source (Olympus, U-ULH) and shutter (Sutter, Lambda 
10-2) operated with Metamorph 10.4 software. LY379268 and/or DHPG were applied for 2 min and 
the maximum increase in fluorescence was reported. All cells included in the analysis exhibited a 
depolarization-induced increase in fluorescence at the end of each experiment to ensure proper 
whole-cell access and potential for somatic Ca2+ mobilization. All Ca2+ imaging experiments were 
performed at -70 mV in the presence of tetrodotoxin (0.5-1 µM) and the mGlu1 receptor NAM, 
VU0469650 (10 µM), to isolate neuron-autonomous, mGlu5 receptor-mediated responses. 
 
2.13 Quantification and statistical analysis 
Significance was assessed using the parametric Student’s t test, for single comparisons, or ANOVA 
and post hoc Fisher’s LSD test or Bonferroni post-test, for multiple comparisons. In the text, values 
are reported as means ± S.E.M.; in the Figure legends, values are reported as means ± S.E.M., 
significance is reported either at the p < 0.05 or p < 0.01 level and n values, t values and F values 
are also reported. 
 
 
3. Results 
 
3.1. Functional interaction between group-I and group-II mGlu receptors in heterologous 
expression systems 
HEK 293 cells were co-transfected with either mGlu1α or mGlu5 receptor cDNA and/or mGlu2 or 
mGlu3 receptor cDNA. Co-transfection did not change expression levels of mGlu1α or mGlu5 
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receptor protein, as detected by immunoblotting (Fig. 1A). In cells expressing mGlu1α or mGlu5 
receptors alone, the mGlu1/5 agonist, (RS)-3,5-dihydroxyphenylglycine (DHPG, 300 µM), 
stimulated PI hydrolysis by about 3-5 fold. This stimulation was unaffected by co-expression of 
either mGlu2 or mGlu3 receptors. The mGlu2/3 receptor agonist, LY379268 (5 µM), which was 
inactive on its own, enhanced DHPG-stimulated PI hydrolysis when mGlu2 or mGlu3 receptors 
were co-expressed with either mGlu1α or mGlu5 receptors. The extent of potentiation by 
LY379268 was similar regardless of receptor combinations (Fig. 1B). To examine whether the 
facilitation of group-I mGlu receptor signaling by group-II mGlu receptors was mediated by the βγ 
subunits of Gi/o proteins we used HEK 293 cells co-expressing mGlu1 or mGlu5 receptors, mGlu3 
receptors, and the C-terminal domain of type-2 G-protein coupled receptor kinase (GRK2-Cter), 
which buffers the βγ subunit (Premont et al., 1995). In these cells, LY379268 failed to amplify 
DHPG-stimulated PI hydrolysis (Fig. 1C).  
 
3.2. Functional interaction between native group-I and group-II receptors is restricted to mGlu3 
and mGlu5 receptors  
Pharmacological activation of group-II mGlu receptors with non-subtype selective agonists 
potentiates group-I mGlu receptor-mediated PI hydrolysis in rat hippocampal slices (Nicoletti et al., 
1993; Genazzani et al., 1994; Schoepp et al., 1996). We reproduced these findings in mouse cortical 
slices, where LY379268 amplified DHPG-stimulated PI hydrolysis in a concentration-dependent 
fashion (Fig. 2A). Knowing that mGlu receptor-mediated PI hydrolysis is developmentally 
regulated (Nicoletti et al., 1986a), we examined the interaction between group-I and group-II mGlu 
receptors at different postnatal ages. At PND9/10, 100 µM DHPG stimulated PI hydrolysis by as 
much as 14-fold. This response was saturating, and, therefore, could not be amplified by LY379268 
(Fig. 2B). Potentiation by LY379268 at this age could be demonstrated by using lower 
concentrations of DHPG (10 µM), which stimulated PI hydrolysis by about 4-5 fold (see Fig. 3E). 
At PND11/12, PND13/14, PND30 and PND60, LY379268 significantly enhanced the stimulation 
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of PI hydrolysis induced by 100 µM DHPG (Fig. 2B). Unexpectedly, LY379268 alone could 
stimulate PI hydrolysis by less than two-fold at PND9/10 and PND11/12, but not at later 
developmental ages (Fig. 2B, reproduced on a different scale in Fig. 2B’).  
To unravel the identity of the group-II mGlu receptor subtype that functionally interacts with group-
I receptors, we used mice with genetic deletion of either mGlu2 or mGlu3 receptors. At PND13/14 
and PND60, potentiation of DHPG-stimulated PI hydrolysis by LY379268 was maintained in 
cortical slices prepared from mGlu2-/- mice, but was lost in slices from mGlu3-/- mice (Fig. 3B,C). 
At PND9/10, stimulation of PI hydrolysis by saturating concentrations of DHPG (100 µM) was 
similar in wild-type and mGlu2-/- mice, but was halved in mGlu3-/- mice (Fig. 3A). In mGlu3-/- mice 
at PND9/10, LY379268 did not potentiate DHPG-stimulated PI hydrolysis, although the PI 
response was submaximal (Fig. 3A). Stimulation of PI hydrolysis by LY379268 alone in PND9/10 
cortical slices was maintained in mGlu2-/- mice, but not in mGlu3-/- mice (Figure 3A shown in a 
different scale in Fig. 3A’). In different sets of experiments, we treated cortical slices from wild-
type mice with the selective mGlu3 receptor negative allosteric modulator (NAM), VU0650786 
(Engers et al., 2015) or with the selective mGlu2 receptor NAM, VU6001966 (Bollinger et al., 
2017). In slices from PND8/9 mice, stimulation of PI hydrolysis by saturating concentrations of 
DHPG (100 µM) was reduced by VU0650786 in a concentration-dependent fashion (Fig. 3D). 
Maximally effective concentrations of VU0650786 halved the PI response to DHPG similarly to 
what found in slices prepared from mGlu3-/- mice (compare Fig. 3D and Fig. 3A). VU0650786 
inhibited the enhancing effect of LY379268 on PI hydrolysis induced by sub-saturating 
concentrations of DHPG (10 µM) at PND8/9 (Fig. 3E) or by saturating concentrations of DHPG 
(100 µM) at PND13/14 (Fig. 3F). We also examined whether stimulation of PI hydrolysis by DHPG 
alone or combined with LY379268 was affected by co-incubation with the mGlu2 NAM 
VU6001966. VU6001966 was applied to cortical slices from PND13/14 mice at concentration of 10 
µM, which is more than 10-fold greater that the IC50 for mGlu2 receptors, and does inhibit mGlu3 
receptors ((Bollinger et al, 2017). In contrast to the mGlu3 receptor NAM, VU0650786, addition of 
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VU6001966 did not attenuate the amplification of DHPG-stimulated PI hydrolysis by LY379268 
(Fig. 3G), and unexpectedly induced a modest enhancement.  
We next examined which of the two group-I subtypes (i.e., mGlu1 or mGlu5) were positively 
modulated by mGlu3 receptors using either subtype-selective drugs or mice lacking mGlu5 or 
mGlu1 receptors. The ability of LY379268 to potentiate DHPG-stimulated PI hydrolysis was 
preserved in slices treated with the mGlu1 receptor NAM, JNJ16259685 (10 µM) (2.5 fold 
potentiation in both control and JNJ16259685-treated slices), whereas it was lost in slices treated 
with MPEP (Fig. 3H).  
Stimulation of PI hydrolysis by 100 µM DHPG was halved in cortical slices from mGlu5-/- mice at 
PND15, as compared to their wild-type counterparts. LY379268 amplified the PI response to 
DHPG in slices from wild-type mice but not in slices from mGlu5-/- mice (Fig. 3I). In contrast, the 
lack of mGlu1 receptors in crv4 mice did not affect the ability of LY379268 to enhance DHPG-
stimulated PI hydrolysis (Fig. 3J). 
 
3.3. mGlu3 receptor activation potentiates mGlu5 receptor-mediated calcium mobilization in 
cortical pyramidal cells 
To examine whether the mGlu3 and mGlu5 receptors interact in neurons we performed Ca2+ 
imaging experiments in acute slices prepared from the mouse PFC. Individual, regular-spiking 
pyramidal cells were identified and loaded with Fluo-4. To isolate neuron-autonomous, mGlu5 
receptor-specific, Ca2+ responses, all experiments were performed in the presence of tetrodotoxin 
and the selective mGlu1 receptor NAM, VU0469650 (Lovell et al., 2013). Strong activation of the 
pyramidal cells with DHPG (100 µM) generated immediate, sharp (4-5 sec) peaks in Fluo-4 
fluorescence that often recurred with a 30-40-sec interval (Fig. 4A). On average, neither a threshold 
concentration of DHPG (30 µM) nor a high concentration of LY379268 (100 nM) was sufficient to 
generate large spikes in somatic Ca2+ mobilization on its own. However, the combination of 
threshold DHPG and LY379268 induced a robust Ca2+ response following co-application. The 
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synergy between LY379268 and DHPG was abrogated when experiments were performed in the 
presence of the mGlu3 receptor NAM, VU0650786 (10 µM) (Fig. 4B), confirming that mGlu3 
receptor activation potentiates postsynaptic neuronal signaling mediated by mGlu5 receptors. 
 
3.4. Pharmacological activation of mGlu3 receptors slightly enhanced DHPG-stimulated PI 
hydrolysis in astrocytes 
We also assessed PI hydrolysis in primary cultures of astrocytes prepared from the mouse cerebral 
cortex. In confluent astrocytes grown in the presence of serum, DHPG failed to stimulate PI 
hydrolysis when applied either alone or in combination with LY379268. When astrocytes were 
switched from a serum-containing medium to a serum-free medium supplemented with a cocktail of 
trophic factors, cells adopted a reactive-like phenotype characterized by increased expression of 
glial fibrillary acid protein. Reactive astrocytes expressed the transcript of mGlu3 and mGlu5 
receptors, but not the transcript of mGlu1 and mGlu2 receptors, as assessed by real-time PCR (not 
shown). In these cells DHPG stimulated PI hydrolysis to an extent that depended on the percentage 
of astrocytes bearing a reactive phenotype. Treatment with LY379268 (1 µM) did not affect 
stimulation of PI hydrolysis by saturating concentrations of DHPG (100 µM) (Supplementary Fig. 
1A). Using lower concentrations of DHPG (20 µM), we could observe a slightly potentiation by 
LY379268, which was abrogated by the mGlu3 NAM, VU0650786 (10 µM) (Supplementary Fig. 
1B). DHPG did not stimulate PI hydrolysis in resting astrocytes when applied alone or in 
combination with LY379268 (Supplementary Fig. 1A). 
 
3.5. mGlu3 and mGlu5 receptors synergize to induce LTD in the PFC  
To study the functional relevance of interactions between mGlu3 and mGlu5 receptors in neurons, 
we measured drug-induced changes in excitatory synaptic transmission in the mouse PFC. 
Pharmacological activation of mGlu3 receptors has previously been shown to induce LTD of 
excitatory transmission in the PFC (Walker et al., 2015). We used whole-cell voltage-clamp 
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recordings from PFC layer V pyramidal cells to determine whether activation of mGlu5 receptors 
can enhance induction of mGlu3 receptor-mediated LTD in this region. To evaluate the effect of 
mGlu5 receptor activation on threshold LTD, a low concentration of LY379268 (100 nM) was 
applied to PFC slices for 3 min. This relatively brief application of LY379268 was not sufficient to 
induce LTD (Fig. 5A, grey bar, 102 ± 14% baseline, n = 4), and application of DHPG (100 µM) 
induced a transient depression of synaptic transmission, but did not induce LTD in the PFC (Fig. 
5B, 108 ± 15% baseline, n = 4). We then co-applied both agonists for the same 3-min period and 
observed a persistent LTD at least 30 min following drug wash-out (Fig. 5C,D, 65 ± 4% baseline, n 
= 5). To confirm that mGlu3 and mGlu5 receptors mediate this LTD, we used the selective mGlu3 
and mGlu5 receptor NAMs, VU0650786 and MTEP, respectively. Application of either 
VU0650786 (Fig. 5E, 94 ± 11% baseline, n = 4) or MTEP (Fig. 5F, 100 ± 12% baseline, n = 4) 
blocked LTD, suggesting that mGlu3 and mGlu5 receptors act synergistically in native tissue to 
generate long-lasting changes in excitatory synaptic transmission. 
As we and others have shown (Walker et al., 2015; Huang et al., 2008; Kasanetz et al., 2013), a 
more prolonged 10-min bath application of LY379268 induces saturating LTD (Fig. 6A,B, 54 ± 7% 
baseline, n = 5). Through selective pharmacology and genetic studies, we previously demonstrated 
that this LTD is mediated by activation of mGlu3, and not mGlu2 receptors (Walker et al., 2015). 
Moreover, others have implicated several molecules related to Gq-signaling in this mGlu3 receptor-
dependent LTD, including PKC and IP3 receptors (Otani et al., 2002; Huang et al., 2007). These 
previous studies were somewhat perplexing in light of the fact that mGlu3 receptor was not thought 
to activate Gq-signaling.  However, based on the present findings, we postulated that co-activation 
of mGlu3 and mGlu5 receptors may be required for induction of mGlu3 receptor-LTD in the PFC. 
Consistent with this hypothesis, the mGlu5 receptor NAM MTEP blocked the induction of mGlu3 
receptor-LTD (Fig. 6C,D, 89 ± 10% baseline, n = 5), suggesting that constitutive mGlu5 receptor 
activity, or activation of mGlu5 receptors by endogenous glutamate, is necessary for mGlu3 
receptor-mediated synaptic plasticity. A synopsis of all LTD data is shown in Supplementary Fig. 2. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18
 
3.6. mGlu5 receptor-mediated enhancement of excitotoxic neuronal death requires the activation of 
mGlu3 receptors 
To study the relevance of the functional partnership between mGlu3 and mGlu5 receptors in 
mechanisms of neurodegeneration, we used pure cultures of rat cortical neurons challenged with 
toxic concentrations of NMDA. Neurons were exposed for 20 min to NMDA, and neuronal death 
was assessed after 22-24 hr by either trypan blue staining or the methyltetrazolium test (MTT) 
assay. DHPG (100 µM) and the mGlu3 receptor NAM, VU0650786 (10 µM), were added to the 
medium during the NMDA pulse. All experiments were carried out in the presence of the mGlu1 
receptor NAM, JNJ16259685 (10 µM). DHPG had a small effect on neuronal viability on its own, 
but amplified excitotoxic neuronal death when combined with either 75 or 300 µM NMDA. DHPG 
no longer amplified NMDA toxicity but became neuroprotective when endogenous activation of 
mGlu3 receptors was prevented by co-treatment with VU0650786 (Fig. 7). Of note, VU0650786 
had no effect per se on NMDA toxicity (Fig. 7), suggesting that neuronal mGlu3 receptors 
influence neurodegeneration by shaping the activity of mGlu5 receptors. 
 
 
4. Discussion 
We have shown for the first time that mGlu3 and mGlu5 receptors specifically interact in the CNS 
and that endogenous activation of mGlu3 receptors is required for maximal mGlu5 receptor 
signaling. In addition, endogenous activation of mGlu5 receptors is required for the induction of 
mGlu3 receptor-dependent LTD in the PFC. The demonstration of a functional partnership between 
mGlu3 and mGlu5 receptors sheds new light into the complex role played by mGlu receptors in 
mechanisms of synaptic plasticity during development and in adulthood, and provides compelling 
rationale for evaluating mGlu3 receptor modulators as potential treatments in CNS disorders 
associated with altered mGlu5 receptor function. 
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There are multiple examples in which mGlu receptor subtypes coupled to Gi have been shown to 
interact with other receptors coupled to Gq and vice versa (Aghajanian and Marek, 2000; Marek et 
al., 2000; Tabata et al., 2004; Gonzàlez-Maeso et al., 2008; Rives et al., 2009; Iacovelli et al., 
2017). However, this is the first time that a partnership between two mGlu receptor subtypes 
coupled to different G proteins is shown in neurons. 
mGlu receptor subtypes form homo- and heterodimers (Romano et al., 2001; Goudet et a., 2005; El 
Moustaine et al., 2012; Kammermeier, 2012; Yin and Niswender, 2014), but mGlu5 receptors are 
not thought to form inter-group heterodimers with either mGlu2 or mGlu3 receptors (Doumazane et 
al., 2011; Sevastyanova and Kammermeier, 2014). Thus, the interactions between mGlu3 and 
mGlu5 receptors shown here are likely mediated by cross-talk of signaling pathways and not by 
heterodimer interactions. Consistent with this, in HEK 293 cells functional interaction between 
mGlu3 and mGlu5 receptors was abrogated by expression of the C-terminal domain of GRK-2, 
which buffers the βγ subunits of G proteins (Premont et al., 1995). This suggests that mGlu3 
receptors boost mGlu5 receptor signaling via the βγ subunits released from Gi proteins, which act 
synergistically with Gq in activating phospholipase-Cβ (Wang et al., 1999).  
In heterologous expression systems, activation of both mGlu2 and mGlu3 receptors could amplify 
PI hydrolysis stimulated by either mGlu1 or mGlu5 receptors, suggesting that any group-II mGlu 
receptor (coupled to Gi) can functionally interact to any group-I mGlu receptor (coupled to Gq) 
when receptors are artificially co-expressed in same cells. This implies that under native conditions 
the interaction between mGlu3 and mGlu5 receptors is specific because the two receptors are co-
localized in subcellular compartments, or that cell type-specific scaffolding proteins tightly regulate 
mGlu receptor interactions. This contrasts with the general belief that neuronal mGlu3 receptors are 
predominantly (albeit not exclusively) localized in presynaptic terminals, whereas mGlu5 receptors 
are found in postsynaptic densities (Nicoletti et al., 2011). We could demonstrate the synergism 
between mGlu3 and mGlu5 receptors in layer V pyramidal neurons of the PFC under conditions in 
which transynaptic action potential-driven events were blocked by tetrodotoxin. These findings 
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suggest that postsynaptic mGlu3 receptors amplify mGlu5 receptor signaling in neurons, consistent 
with recent electron microscopy data showing that mGlu3 receptors are concentrated in 
postsynaptic locations in the PFC (Jin et al., 2017). Activation of postsynaptic mGlu3 receptors 
induces LTD in the medial PFC (Walker et al., 2015), a particular form of activity-dependent 
synaptic plasticity that plays a key role in medial PFC-dependent cognitive functions (Walker et al., 
2015; Kasanetz et al., 2013; Otani et al., 1999). Accordingly, selective blockade of mGlu3 receptors 
disrupts learning in a medial PFC-fear extinction task (Walker et al., 2015), and polymorphic 
variants of the GRM3 (the gene encoding mGlu3 receptors) are associated with poor performance in 
PFC-dependent cognitive tasks (Egan et al., 2004; Harrison et al., 2008). We demonstrated here that 
induction of mGlu3 receptor-dependent LTD requires the endogenous activity of mGlu5 receptors. 
This finding is consistent with previous reports demonstrating that PFC mGlu3-LTD is blocked by 
inhibitors of proteins involved in canonical Gq signaling, such as PLC and PKC (Otani et al., 2002; 
Huang et al., 2007). On the other hand, Otani et al. (2002) concluded that group-I mGlu receptors 
are not involved in PFC mGlu3-LTD. Several mechanistic and technical differences may account 
for the discrepancy between that interpretation and ours. For one, Otani et al., performed recordings 
in slices prepared from the juvenile rat PFC. In light of the pronounced developmental changes 
observed in the present study, it would not be surprising if mechanistic differences in mGlu receptor 
synaptic plasticity exist at these different stages. Consistent with that possibility, Otani et al., 
implicated NMDA receptor activation in mGlu3-LTD, whereas recent studies from our lab and 
others show that NMDA receptor activity is not required (Walker et al., 2015; Huang et al., 2008). 
Furthermore, Otani et al., used the mGlu1-preferring antagonist AIDA, which may not have 
efficiently blocked mGlu5 receptor activation. Alternatively, we utilized highly selective NAMs to 
inhibit mGlu5 function. In addition to selectivity, the contrasting modes of inhibition (i.e. 
orthosteric antagonist vs. allosteric inverse agonist) could factor into the difference in findings. 
While further investigation into the mechanism is warranted, the finding that the mGlu5 receptor is 
required for mGlu3-mediated synaptic plasticity is of great relevance in physiology and pathology. 
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Cognitive dysfunction caused by abnormalities in synaptic plasticity in the PFC lies at the core of 
schizophrenia and other psychiatric disorders (Carpenter and Buchanan, 1994; Tamminga and 
Holcomb, 2005; Falkai et al., 2015). Our findings suggest that the functional partnership between 
mGlu5 and mGlu3 receptors cannot be ignored in the design of new nootropic drugs that target 
mGlu5 receptors. Moreover, mGlu3 receptors might modulate synaptic plasticity in brain regions 
that express prominent mGlu5-mediated plasticity. With that in mind, modulators of mGlu3 
receptor signaling may hold therapeutic potential in a host of disease states that have yet to be 
considered. 
One of the most striking features of mGlu5 receptors is that agonist-stimulated PI hydrolysis is 
extraordinarily large during the first 10 days of postnatal life, and progressively declines afterwards 
(Nicoletti et al., 1986a; Casabona et al., 1997). mGlu5 receptors are involved in mechanisms of 
developmental plasticity, and drive key events in the formation of the cortical somatosensory map 
(Hannan et al., 2001; Wijetunge et al., 2008; Loerwals et al., 2015; Ballester-Rosado et al., 2016). 
mGlu5 receptors are necessary for the development of fast-spiking GABAergic interneurons, which 
regulate the synchronous firing of pyramidal neurons and are critical for the generation of network 
oscillations in the PFC (Barnes et al., 2015; Luoni et al., 2016). We were surprised to find that 
endogenous activation of mGlu3 receptors was required for the full efficiency of mGlu5 receptor-
mediated PI hydrolysis in the first 10 days of postnatal life. In addition, pharmacological activation 
of mGlu3 receptors with LY379268 was sufficient to stimulate PI hydrolysis in the first 12 days of 
postnatal development. This unexpected effect might be explained by amplification of greater 
constitutive activity of mGlu5 receptors during this early developmental stage. The finding that 
LY379268 alone did not stimulate PI hydrolysis at later stages might reflect the developmental 
decline of mGlu5 receptors (Casabona et al., 1997; Catania et al., 1994). We suggest that the 
functional partnership between mGlu3 and mGlu5 receptors is instrumental for the large stimulation 
of PI hydrolysis in the early phases of postnatal development, when high levels of intracellular Ca2+ 
are required for mechanisms of developmental plasticity. Of note, expression of both mGlu3 and 
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mGlu5 receptors is high in the early postnatal brain, and progressively declines across postnatal 
development (Catania et al., 1994; Lòpez-Bendito et al., 2002). Genetic variants of GRM3 are 
associated with schizophrenia (Fujii et al., 2003; Egan et al., 2004; Chen et al., 2005; Norton et al., 
2005; Bishop et al., 2007; Schwab et al., 2008), and dimerization of mGlu3 receptors is altered in 
the PFC of patients affected by schizophrenia (Corti et al., 2007). Abnormalities in mGlu3 receptor 
expression or function may disrupt the functional partnership between mGlu3 and mGlu5 receptors, 
with detrimental consequences during critical time windows of postnatal development. Preclinical 
studies indicate that mGlu5 receptor positive allosteric modulators (PAM) are putative candidate 
drugs in the treatment of schizophrenia (Kinney et al., 2005; Rodriguez et al., 2010; Vinson and 
Conn, 2012). Group-II mGlu receptor agonists have also shown antipsychotic-like effects in 
preclinical models, but selective mGlu2 PAMs have failed to reach the clinic. Together, these data 
suggest that selective PAMs of mGlu3 receptors may hold promise in treating schizophrenia and 
confer antipsychotic or nootropic benefits by potentiating mGlu5 receptor signaling. Moreover, our 
data suggest that the efficacy of mGlu5 receptor PAMs may be suboptimal in schizophrenic patients 
with a defective expression or function of mGlu3 receptors, and perhaps a multimodal drug 
amplifying both mGlu3 and mGlu5 receptors would be highly valuable in the treatment of cognitive 
dysfunction associated with schizophrenia. 
Our data may also have a strong impact on the study of mGlu receptors in mechanisms of 
neurodegeneration/neuroprotection (Bruno et al., 2017). Activation of mGlu5 receptors may either 
support or dampen neuronal viability depending on the experimental paradigm of neurotoxicity 
(Nicoletti et al., 1999; Bruno et al., 2001; 2017), whereas pharmacological blockade of mGlu5 
receptors is consistently neuroprotective in a variety of models of neurodegenerative disorders 
(Battaglia et al., 2002; 2004; Masilamoni et al., 2011; Hamilton et al., 2014). Glial mGlu3 receptors 
are neuroprotective via a paracrine mechanism mediated by the production of neurotrophic factors, 
(Bruno et al., 1998; Battaglia et al., 2009; 2015; Caraci et al., 2011), whereas the role of neuronal 
mGlu3 receptors in neurodegeneration/neuroprotection is unknown. Using pure cultures of cortical 
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neurons, we have shown that pharmacological activation of mGlu5 receptors amplified excitotoxic 
neuronal death, and this effect was abrogated by the mGlu3 receptor NAM, VU0650786. 
Interestingly, activation of mGlu5 receptors became neuroprotective in the presence of VU0650786, 
which had no effect on NMDA toxicity on its own. This suggests that mGlu5 receptors may either 
amplify or restrain neuronal toxicity and the balance between these two functions is critically 
regulated by mGlu3 receptors. Thus, the expression and function of mGlu3 receptors may shape the 
role of mGlu5 receptors in mechanisms of neurodegeneration/neuroprotection. This novel 
mechanism raises concern about the use of mGlu3 receptor agonists or PAMs as potential 
neuroprotective agents in the treatment of Parkinson’s disease and other chronic neurodegenerative 
disorders (Bruno et al., 2017). Perhaps the combination of mGlu3 PAMs and mGlu5 NAMs might 
represent an optimal therapeutic option to slow the progression of chronic neurodegenerative 
disorders. 
In conclusion, the demonstration of the functional partnership between mGlu3 and mGlu5 receptors 
may have important implications in physiology and pathology and stimulates reconsideration of the 
existing literature on mGlu3 and mGlu5 receptors from a different angle. The high expression of 
mGlu3 and mGlu5 receptors during early postnatal development may be an absolute requirement to 
ensure an efficient stimulation of PI hydrolysis that is essential for mechanisms of developmental 
plasticity, and CNS disorders which are related to a defective activation of mGlu5 receptors, such as 
schizophrenia, might be caused by a disrupted functional interaction between the two receptors. On 
the other hand, mGlu3 receptors might have a role in disorders characterized by an over-activity of 
mGlu5 receptors, such as Fragile X and other types of monogenic autism. It remains to be 
determined whether the pharmacodynamic boosting mediated by mGlu3 receptors is restricted to 
mGlu5 receptor-stimulated PI hydrolysis or is extended to other intracellular transduction 
mechanisms. 
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Figure legends  
 
Fig. 1 – Functional cross-talk between group-I and group-II mGlu receptors in transfected 
HEK 293 cells. 
Expression of mGlu1 and mGlu5 receptors in cells transfected with mGlu1 or mGlu5 cDNA in the 
absence or presence of mGlu2, mGlu3 receptors or GRK2-C-ter cDNA is shown in (A). Stimulation 
of PI hydrolysis by DHPG and/or LY379268 in cells expressing mGlu1 or mGlu5 receptors with or 
without mGlu2 or mGlu3 receptors is shown in (B). The effect of GRK2-C-ter on the synergism 
between mGlu3 and mGlu1 or mGlu5 receptors is shown in (C). In (B) and (C), values are mean ± 
S.E.M. of 3-9 determinations. p<0.05 (Two-way ANOVA + Bonferroni test) * vs. the respective 
basal and # vs. the respective DHPG alone (B1: F(1,16) = 4.69 for transfection factor and F(3,16) = 
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43.93 for treatment factor; B2: F(1,16) = 11.39 for transfection factor and F(3,16) = 112.73 for treatment 
factor; B3: F(1,25) = 2.17 for transfection factor and F(3,25) = 27.00 for treatment factor; B4: F(1,47) = 
1.04 for transfection factor and F(3,47) = 41.17 for treatment factor; C1: F(1,25) = 4.89 for transfection 
factor and F(3,25) = 28.97 for treatment factor; C2: F(3,29) = 30.78 for treatment factor).  
 
Fig. 2 – Functional partnership between group-II and group-I mGlu receptors in mouse 
cortical slices at different developmental ages. 
Concentration-dependent amplification of DHPG-stimulated PI hydrolysis by LY379268 in cortical 
slices of mice at PND30 is shown in (A). The age-dependent profile of DHPG-stimulated PI 
hydrolysis in the absence or presence of LY379268 is shown in (B). Data with LY379268 alone are 
highlighted in (B’). Values are mean ± S.E.M. of 3-4 determinations. p<0.05 (One-way ANOVA + 
Fisher’s LSD in A and B and Student’s t test in B’) vs. the respective basal (*), DHPG (#). (A): 
F(8,27) = 22.49; (B): F(3,11) = 840.6 (PND9/10); F(3, 8) = 132.27 (PND11/12); F(3,8) = 263.84 
(PND13/14); F(3,12) = 29.46 (PND30); F(3,12) = 45.25 (PND60); (B’): t(5) = -4.84 (PND9/10); t(4) = -
5.32 (PND11/12). 
 
Fig. 3 – Functional partnership between native group-I and group-II mGlu receptors is 
mediated by mGlu3 and mGlu5. 
Stimulation of PI hydrolysis by DHPG and/or LY379268 in cortical slices prepared from wild-type, 
mGlu2-/-  and mGlu3-/- mice are shown in (A-C), where wild-type data at PND9/10 and 60 are the 
same data as in Figure 2B for comparative purposes. Data with LY379268 at PND9/10 are 
highlighted in (A’). The effect of the mGlu3 receptor NAM, VU0650786, on DHPG/LY379268-
stimulated PI hydrolysis is shown in (D-F). The effect of the mGlu2 receptor NAM, VU6001966, 
on DHPG/LY379268-stimulated PI hydrolysis is shown in (G). The effect of the mGlu1 receptor 
NAM, JNJ16259685, and the mGlu5 receptor NAM, MPEP, on DHPG/LY379268-stimulated PI 
hydrolysis is shown in (H), where control data are the same data as in Figure 2B at PND13/14 for 
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comparative purposes. Stimulation of PI hydrolysis by DHPG/LY379268 in cortical slices from 
mGlu5-/- or crv4 mice and their wild-type counterparts is shown in (I) and (J), respectively. Values 
are mean ± S.E.M. of 3-5 determinations. p<0.05 (Two-way ANOVA + Bonferroni test) * vs. the 
respective basal values and # vs. the DHPG alone or DHPG+LY379268 values obtained in wild-
type and mGlu2-/- mice  (A: F(2,33) = 110.73 for genotype factor and F(3,33) = 693.82 for treatment 
factor; A’: F(2,15) = 36.15 for genotype factor and F(3,15) = 77.46 for treatment factor; B: F(2,30) = 
36.33 for genotype factor and F(3,30) = 235.35 for treatment factor; C: F(2,35) = 24.79 for genotype 
factor and F(2,35) = 40.05 for treatment factor). p<0.05 (Two-way ANOVA + Bonferroni test) * vs. 
the respective basal values and # vs. the DHPG values (D: F(1,26) = 913.61 for Basal/DHPG factor 
and F(4,26) = 13.95 for VU0650786 concentrations factor; E: F(1,14) = 70.67 for Basal/DHPG factor 
and F(3,14) = 57.33 for drugs factor; F: F(3,31) = 29.60 for drugs factor and F(2,31) = 8.56 for 
VU0650786 concentrations factor; G: F(3,28) = 234.24 for drugs factor and F(1,28) = 9.89 for 
VU6001966 concentrations factor; H: F(2,24) = 93.54 for drugs - JNJ16259685 and MPEP -  factor 
and F(3,24) = 284.48 for treatment factor. p<0.05 (Two-way ANOVA + Bonferroni test) * vs. the 
respective basal values and # vs. the respective DHPG alone values (I: F(1,32) = 2826.74 for 
genotype factor and F(3,32) = 1763.58 for treatment factor; J: F(1,22) = 160.79 for genotype factor and 
F(3,22) = 236.83 for treatment factor). 
 
Fig. 4 – mGlu 3 receptor activation enhances mGlu5 receptor-mediated somatic Ca2+ 
mobilization in pyramidal cells of the mouse PFC. 
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(A) Representative calcium imaging fluorescence experiments. To isolate neuron-autonomous, 
mGlu5 receptor-specific calcium responses, all experiments were performed in the presence of 
tetrodotoxin and the selective mGlu1 receptor NAM, VU0490650 (10 µM). Pyramidal cells were 
loaded with the cell-impermeable fluorescent calcium indicator Fluo-4. (B) Summary of calcium 
imaging experiments. Values are mean ± S.E.M. *p< 0.05, **p < 0.01, Bonferroni post-tests. 
 
Fig. 5 – mGlu3 and mGlu5 receptors synergize to induce LTD in the mouse PFC.  
(A) Application of the mGlu2/3 receptor agonist LY379268 (100 nM) for 3 min does not generate a 
long-term change in the amplitude of the excitatory postsynaptic current (EPSC) (102 ± 14% 
baseline, n = 4). (B) Application of the mGlu1/5 receptor agonist DHPG (100 µM) for 3 min does 
not alter long-term excitatory transmission (108 ± 15% baseline, n = 4). (C) Representative 
experiment showing LTD induced by the combined bath application of LY379268 and DHPG. 
Inset, representative EPSC traces before and after LTD. Scale bars denote 50 ms and 50 pA. (D) 
Summary time course of LTD experiments (65 ± 4% baseline, n = 5). (E) VU0650786 blocked the 
induction of LTD (94 ± 11% baseline, n = 4). (F) MTEP blocked the induction of LTD (100 ± 12% 
baseline, n = 4). Values are mean ± S.E.M. in A-F. 
 
Fig. 6 – Saturating mGlu3 receptor-LTD requires the activation of mGlu5 receptors. 
mGlu3 receptor-dependent-LTD requires activation of mGlu5 receptors. (A) Representative 
experiment displaying LTD of excitatory transmission following bath application of the mGlu2/3 
receptor agonist LY379268 (100 nM) for 10 min. Inset, representative excitatory postsynaptic 
current (EPSC) before and after LTD. All scale bars denote 100 ms and 100 pA. (B) Summary of 
LTD experiments. LY379268 induces LTD (54 ± 7% baseline, n = 5). (C) Representative 
experiment following application of the selective mGlu5 receptor NAM, MTEP (10 µM). (D) 
MTEP blocked the induction of LTD (89 ± 10% baseline, n = 5). Values are mean ± S.E.M. in A-D.  
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Fig. 7 – Amplification of NMDA toxicity by DHPG in rat cortical neurons requires the 
endogenous activation of mGlu3 receptors. 
Pure cultures of rat cortical neurons were challenged with either 75 or 300 µM NMDA for 20 min 
in the absence or presence of DHPG and/or the mGlu3 receptor NAM, VU0650786. The 
experiment was carried out in the presence of the mGlu1 receptor NAM, JNJ16259685 (10 µM), to 
avoid the stimulation of mGlu1 receptors by DHPG. Neuronal toxicity was assessed by trypan blue 
staining. Values are means ± S.E.M. of 4 determinations. p<0.05 (One-way ANOVA + Fisher’s 
LSD) vs. the respective basal values (*), the vehicle values of the same group (NMDA alone) (#), or 
vs. the respective DHPG values of the same group (§). F(11,36) = 177.91. This experiment was 
repeated twice and data were confirmed by using the MTT assay. 
 
Supplementary Fig. 1 – LY379268 slightly enhanced DHPG-stimulated PI hydrolysis in 
mouse cultured astrocytes. 
In (A), cultures were challenged with 100 µM DHPG and/or LY379268 (1 µM). Values are means 
+ S.E.M. of 6 determinations. p<0.05 (One-way ANOVA + Fisher’s LSD) as compared to Basal 
(*). F(3,20) = 94.58. In (B), cultured astrocytes bearing a reactive phenotype were challenged with 20 
µM DHPG combined with LY379268 (1 µM) and VU0650786 (10 µM). Values are means + 
S.E.M. of 4 determinations. p<0.05 (One-way ANOVA + Fisher’s LSD) as compared to Basal (*), 
to DHPG alone (#) or DHPG + LY379268 ($). F(3,12) = 41.79. The percentage of astrocytes with a 
reactive phenotype was greater in (A) than in (B). 
 
Supplementary Fig. 2 – A synopsis of all LTD values. Brief, 3-min co-application of LY379268 
(100 nM) and DHPG (100 µM) induced LTD of the excitatory postsynaptic current (EPSC) 
(*p<0.05, one-sample t-test vs. 100% baseline). Selective negative allosteric modulators (NAMs) 
for mGlu3 (VU0650786) or mGlu5 (MTEP) blocked the LTD. Saturating mGlu3 receptor-LTD was 
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induced with prolonged, 10-min application of LY379268 (*p<0.05, one-sample t-test vs. 100% 
baseline). Saturating mGlu3 receptor-LTD was also blocked by MTEP (3 µM) application. 
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• mGlu5 and mGlu3 receptors functionally interact in the central nervous system  
• mGlu3 receptors support mGlu5 receptor signaling in the early postnatal life 
• mGlu3 receptor activation potentiate mGlu5 receptor-mediated somatic Ca2+ mobilization 
• mGlu3 and mGlu5 receptors interact to induce LTD in the prefrontal cortex 
• This interaction is relevant to mechanisms of neuronal toxicity 
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